These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 3334665)

  • 1. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer.
    Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F
    Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665
    [No Abstract]   [Full Text] [Related]  

  • 2. [Granulomatous prostatitis after intravesical BCG immunotherapy of superficial bladder cancer: a case report].
    Sai S; Sakakibara T; Takashi M; Sakata T; Miyake K
    Hinyokika Kiyo; 1990 Aug; 36(8):953-5. PubMed ID: 2239600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCG in bladder cancer.
    Meek D
    Nurs Times; 1994 Oct 26-Nov 1; 90(43):34-5. PubMed ID: 7984457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
    Aso Y; Akaza H; Kameyama S; Niijima T
    Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
    [No Abstract]   [Full Text] [Related]  

  • 5. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer.
    Zlotta AR; Drowart A; Van Vooren JP; de Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    J Urol; 1997 Feb; 157(2):492-8. PubMed ID: 8996341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tubercular prostatic abscess as a complication of intravesical bacillus Calmette-Guérin immunotherapy.
    Aust TR; Massey JA
    Int J Urol; 2005 Oct; 12(10):920-1. PubMed ID: 16323989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
    van der Meijden AP
    Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591
    [No Abstract]   [Full Text] [Related]  

  • 8. [Miliary tuberculosis after intravesical Bacillus Calmette-Guerin administration].
    Reparaz J; Uriz J; Castiello J; Sola J
    Enferm Infecc Microbiol Clin; 1993 Dec; 11(10):570. PubMed ID: 8142511
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravesical and intradermal BCG-RIVM application: a toxicity study.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Wagenaar J; Feitz WF; Hendriks B; de Jong WH; Steeren-Berg PA
    Prog Clin Biol Res; 1985; 185B():151-9. PubMed ID: 4034587
    [No Abstract]   [Full Text] [Related]  

  • 10. [The intravesical administration of BCG vaccine in treating recurrent superficial bladder cancer].
    Panteleeva ES; Neprina GS; Vatin OE; Kariakin OB; Safiullin KN
    Urol Nefrol (Mosk); 1997; (2):29-32. PubMed ID: 9206879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Reiter syndrome after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy: a case report].
    Shiba M; Fujii T; Takatera H
    Hinyokika Kiyo; 2003 Oct; 49(10):599-601. PubMed ID: 14655604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical administration of Bacille Calmette-Guérin.
    Morgan MB; Iseman MD
    Am J Med; 1996 Mar; 100(3):372-3. PubMed ID: 8629686
    [No Abstract]   [Full Text] [Related]  

  • 13. [Topical BCG therapy of in situ cancer of the urinary bladder].
    Mack D; Jakse G
    Urologe A; 1987 Jan; 26(1):22-5. PubMed ID: 3576860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New-onset psoriasis and psoriatic arthritis in a patient treated with Bacillus Calmette-Guérin (BCG) immunotherapy.
    Dudelzak J; Curtis AR; Sheehan DJ; Lesher JL
    J Drugs Dermatol; 2008 Jul; 7(7):684. PubMed ID: 18664162
    [No Abstract]   [Full Text] [Related]  

  • 16. Nursing aspects of bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
    LeBouton J
    Urol Nurs; 1990 Dec; 10(4):9-14. PubMed ID: 2274796
    [No Abstract]   [Full Text] [Related]  

  • 17. Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.
    Proctor DD; Chopra S; Rubenstein SC; Jokela JA; Uhl L
    Am J Gastroenterol; 1993 Jul; 88(7):1112-5. PubMed ID: 8317415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycobacterial adherence and BCG treatment of superficial bladder cancer.
    Schamhart DH; de Boer EC; Bevers RF; Kurth KH; Steerenberg PA
    Prog Clin Biol Res; 1992; 378():75-80. PubMed ID: 1284504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
    Patard JJ; Chopin DK
    Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.